Cardiovascular Risk
- NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (see WARNINGS) .
- DAYPRO® is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
Gastrointestinal Risk
- NSAID's cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events(see WARNINGS).
|
| |
DAYPRO SUMMARY
DAYPRO®
(oxaprozin) 600mg Caplets
DAYPRO (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID), chemically designated as 4,5-diphenyl-2-oxazole-propionic acid, and has the following chemical structure.
Carefully consider the potential benefits and risks of DAYPRO and other treatment options before deciding to use DAYPRO. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).
DAYPRO is indicated:
- For relief of the signs and symptoms of osteoarthritis
- For relief of the signs and symptoms of rheumatoid arthritis
- For relief of the signs and symptoms of juvenile rheumatoid arthritis
|
NEWS HIGHLIGHTS
Published Studies Related to Daypro (Oxaprozin)
A review of the emerging profile of the anti-inflammatory drug oxaprozin. [2005.05]
Oxaprozin is a nonsteroidal anti-inflammatory drug characterised by a propionic acid-based structure... As monocyte-macrophages and NF-kappaB pathways are crucial for synthesis of proinflammatory and histotoxic mediators in inflamed joints, oxaprozin appears to be endowed with pharmacodynamic properties exceeding those presently assumed as markers of classical nonsteroidal anti-inflammatory drug.
|
|
|
|
Page last updated: 2007-02-12
|
